(08/18/2019)
Last week, I saw my Radiation Oncologist. I signed all the forms to enter a study targeting oligometastatic prostate cancer patients - if early radiation treatment of the metastatic lesions improves survival times.
Of interest is that the prostate shows regression after about 2 ½ months of ADT.
The T6 lesion, however, does not. This brings into question the type of tumor being detected.
I have a biopsy of the T6 lesion next week.
At this point, I'm encouraged.
The primary tumor is noticeably regressed after minimal ADT.
Several weeks of daily radiation treatment to at least the primary tumor will start in a couple of weeks.
The PSA, though initially low, seems to be tracking with the primary tumor.
The single metastatic lesion at T6 will either be treated with radiation or, if found to be a new tumor type, is caught early, hopefully responsive to (chemo?) treatment.
Maybe the light at the end of the tunnel isn't a train after all.
ALKALINE PHOSPHATASE (08/15/2019)
Your Value
90 U/L.
Standard Range <116 U/L
PSA, TOTAL (08/15/2019)
Your Value
1.12 ng/mL
Standard Range <4.00 ng/mL
PSA, TOTAL (06/17/2019)
Your Value
1.2 ng/mL
Standard Range <4.00 ng/mL
((after only about 3 weeks of ADT treatment))
PSA, TOTAL (03/29/2019)
Your Value
2.14 ng/mL
Standard Range <4.00 ng/mL
((before any treatment))
[ed note] as an old Med Tech, having run and reported over a gazillion lab tests - I'm always uncomfortable with interpretations made from changes to the right of the decimal point.
Exerpt from CT Chest Scan (08/15 /2019)
Unchanged mixed lytic and sclerotic lesion of T6 vertebral body without new osseous lesions
Exerpt from CT Chest Scan (5/22/2019)
Mixed sclerotic and lucent lesion in the T6 vertebral body corresponding to increased radiotracer uptake on bone scan, likely representing osseous metastatic disease.
Exerpt from CT Abdomen Scan (08/15 /2019)
Interval decrease in in the size of prostate gland
(08/15 /2019)
((Lupron, 6 month, given May 29th, 2019))